NOMAD POWER SOLUTIONS, INC.
Close on Oct 19, 2026
- Market cap
- $50.26M
- P/E (TTM)
- –
- Dividend yield
- –
About Nomad Power Solutions
Pharmaceutical Preparations, SIC 2834
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical and proton therapy enterprise focused on discovering, developing, and commercializing cancer therapies. The organization centers its primary pharmaceutical pipeline on inhibitors of protein phosphatase 2A, targeting their capability to augment the effectiveness of chemotherapy, radiation, and immunotherapy treatments. Its principal investigational asset, designated as LB-100, is undergoing evaluation across several clinical trials, including investigations for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. In parallel, through its majority ownership in Liora Technologies Europe Ltd., the company develops electronically controlled proton therapy equipment using proprietary linear accelerator systems for tumor radiation.
The enterprise maintains its principal executive headquarters in Boca Raton, Florida. Its operational reach and development programs encompass clinical and institutional collaborations across the United States and Europe, including partnerships and research activities associated with entities located in the Netherlands and Spain, alongside operations tied to its European proton therapy subsidiary.
Summary of the business section of Nomad Power Solutions's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NOMAD POWER SOLUTIONS, INC.
- Headquarters
- Boca Raton, FL
- Address
- 433 Plaza Real, Suite 275 33432
- Phone
- (310) 203-2902
- Website
- nomadpower.com
- Employees
- 3, Dec 31, 2020
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company, P.A, Los Angeles, California
Stock & identifiers
- Ticker
- NMAD
- Exchange
- Nasdaq
- IPO date
- Oct 25, 2007
- Shares outstanding
- 16M, Aug 10, 2026
- Public float
- $1.98M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Aug 9, 2023; 1-for-10 reverse, Jun 5, 2023; 1-for-6 reverse, Mar 26, 2021
- SEC CIK
- 1335105
- CUSIP
- 539319301
- ISIN
- US5393193017
- LEI
- 5493004HPIB1PBNQ3L69
- EIN
- 20-2903526
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Geordan Garrett Pursglove | CEO and Chairman of the Board, Director | 700,000 |
| Peter Stazzone | Chief Financial Officer | 100,000 |
| Guy Warren Primus | Director | 40,000 |
| Michael Andrew Holloway | Director | 40,000 |
| John Francis Travaglini | Director | – |
| Jason David Sawyer | Director | 65,000 |
| Lourdes Felix | Director | 55,000 |
| Stuart D. Porter | Director | 25,000 |
| Yun Yen | Director | 52,632 |
| Stephen J. Forman | Director | 74,804 |
| Regina Brown | Director | 6,300 |
| Rene Bernards | Director | 25,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $153.50K | $94.46K | $562.38K | $17 | – |
| FY2023 | $634.57K | $669.20K | $550.00K | $20 | – |
| FY2022 | $315.64K | $315.53K | $725.74K | $43 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings